Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties.
- Bono, Francoise
- De Smet, Frederik
- Herbert, Corentin
- De Bock, Katrien
- Georgiadou, Maria
- Fons, Pierre
- Tjwa, Marc
- Alcouffe, Chantal
- Ny, Annelii
- Bianciotto, Marc
- Jonckx, Bart
- Murakami, Masahiro
- Lanahan, Anthony A.
- Michielsen, Christof
- Sibrac, David
- Dol-Gleizes, Frederique
- Mazzone, Massimiliano
- Zacchigna, Serena
- Herault, Jean-Pascal
- Fischer, Christian
- Rigon, Patrice
- Ruiz de Almodovar, Carmen
- Claes, Filip
- Blanc, Isabelle
- Poesen, Koen
- Zhang, Jie
- Segura, Inmaculada
- Gueguen, Genevieve
- Bordes, Marie-Francoise
- Lambrechts, Diether
- Broussy, Roselyne
- van de Wouwer, Marlies
- Michaux, Corinne
- Shimada, Toru
- Jean, Isabelle
- Blacher, Silvia
- Noël, Agnès
- Motte, Patrick
- Rom, Eran
- Rakic, Jean-Marie
- Katsuma, Susumu
- Schaeffer, Paul
- Yayon, Avner
- Van Schepdael, Ann
- Schwalbe, Harald
- Gervasio, Francesco Luigi
- Carmeliet, Geert
- Rozensky, Jef
- Dewerchin, Mieke
- Simons, Michael
- Christopoulos, Arthur
- Herbert, Jean-Marc
- Carmeliet, Peter
DOIAbstract
Receptor tyrosine kinases (RTK) are targets for anticancer drug development. To date, only RTK inhibitors that block orthosteric binding of ligands and substrates have been developed. Here, we report the pharmacologic characterization of the chemical SSR128129E (SSR), which inhibits fibroblast growth factor receptor (FGFR) signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding. SSR exhibits allosteric properties, including probe dependence, signaling bias, and ceiling effects. Inhibition by SSR is highly conserved throughout the animal kingdom. Oral delivery of SSR inhibits arthritis and tumors that are relatively refractory to anti-vascular endothelial growth factor receptor-2 antibodies. Thus, oral...
Add to ORKG